Skandinaviska Enskilda Banken AB publ Trims Holdings in Guardant Health, Inc. $GH

Skandinaviska Enskilda Banken AB publ reduced its stake in Guardant Health, Inc. (NASDAQ:GH) by 97.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 731 shares of the company’s stock after selling 23,567 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Guardant Health were worth $46,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Norges Bank acquired a new position in shares of Guardant Health during the 2nd quarter valued at about $64,136,000. Franklin Resources Inc. boosted its holdings in Guardant Health by 78.2% in the 2nd quarter. Franklin Resources Inc. now owns 2,319,947 shares of the company’s stock valued at $120,730,000 after purchasing an additional 1,018,144 shares during the last quarter. Invesco Ltd. grew its stake in shares of Guardant Health by 27.3% in the 2nd quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock valued at $185,184,000 after buying an additional 763,834 shares during the period. Jennison Associates LLC acquired a new stake in shares of Guardant Health during the 2nd quarter worth approximately $37,233,000. Finally, Nikko Asset Management Americas Inc. raised its position in shares of Guardant Health by 49.6% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 2,030,428 shares of the company’s stock valued at $105,623,000 after buying an additional 673,438 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GH has been the subject of several analyst reports. Canaccord Genuity Group increased their price objective on Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday. Mizuho set a $135.00 price target on Guardant Health in a report on Friday, January 9th. Stifel Nicolaus boosted their price objective on shares of Guardant Health from $120.00 to $130.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Thursday, January 22nd. Finally, UBS Group reiterated a “buy” rating and set a $175.00 price target on shares of Guardant Health in a research report on Friday, January 30th. Twenty-one equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Guardant Health currently has an average rating of “Moderate Buy” and an average target price of $117.43.

Key Headlines Impacting Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Insider Activity at Guardant Health

In related news, Director Medina Manuel Hidalgo sold 1,250 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $105.00, for a total value of $131,250.00. Following the sale, the director owned 797 shares of the company’s stock, valued at $83,685. This trade represents a 61.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Helmy Eltoukhy sold 90,565 shares of Guardant Health stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the completion of the transaction, the chief executive officer owned 2,047,143 shares of the company’s stock, valued at $212,534,386.26. This represents a 4.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 434,511 shares of company stock worth $45,580,887 over the last quarter. 6.10% of the stock is currently owned by insiders.

Guardant Health Stock Performance

NASDAQ GH opened at $103.10 on Monday. The firm has a market cap of $13.52 billion, a price-to-earnings ratio of -31.15 and a beta of 1.63. The firm has a 50 day simple moving average of $106.69 and a 200-day simple moving average of $86.51. Guardant Health, Inc. has a one year low of $34.88 and a one year high of $120.74.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million for the quarter, compared to the consensus estimate of $269.74 million. The firm’s quarterly revenue was up 39.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.62) EPS. Equities analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.